Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
These regimens also reduced the risk of death in Brain metastasis (in: Non-Small-Cell Lung Carcinoma (NSCLC)) patients by 29% compared with non-PD-1/L1 inhibitor regimens.
This meta-analysis indicates that PD-1 or PD-L1 inhibitors can reduce risk of both disease progression and death of patients with brain metastases of NSCLC, who have been pretreated with local therapies and/or are asymptomatic for the brain lesions.
see also:
Brain metastasis & Non-Small-Cell Lung Carcinoma (NSCLC)
[Immune Checkpoint Inhibitors (ICIs) & Brain metastasis (in: Non-small cell lung carcinoma (NSCLC))](brain://pYhI5NO1rEOhDqAZNtZmtg/ImmuneCheckpointInhibitorsIC…